The study and its comparison
Sixty patients with schizophrenia or schizoaffective disorder were randomized to 400 milligrams daily of theanine or placebo alongside ongoing antipsychotic treatment. Forty completed the protocol. [1]
Anxiety and selected positive or activation symptoms favored theanine. Negative symptoms, neurocognitive tasks, general functioning and quality of life did not show benefit. [1]
What the finding establishes
The incomplete follow-up and modest sample constrain the conclusion. Studying an adjunct is not evidence to replace antipsychotics, and this trial is not a comprehensive check of interactions with every medicine. The abstract does not establish long-term benefit or safety. Funding and conflicts were not established from the retrieved record. [1]
A hypothetical distinction
Imagine a symptom scale improves while daily functioning does not. Both results belong in an accurate account of treatment benefit.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.